AU2011207253B2 - Anti-ILT5 antibodies and ILT5-binding antibody fragments - Google Patents

Anti-ILT5 antibodies and ILT5-binding antibody fragments Download PDF

Info

Publication number
AU2011207253B2
AU2011207253B2 AU2011207253A AU2011207253A AU2011207253B2 AU 2011207253 B2 AU2011207253 B2 AU 2011207253B2 AU 2011207253 A AU2011207253 A AU 2011207253A AU 2011207253 A AU2011207253 A AU 2011207253A AU 2011207253 B2 AU2011207253 B2 AU 2011207253B2
Authority
AU
Australia
Prior art keywords
seq
ilt5
antibody
amino acid
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011207253A
Other languages
English (en)
Other versions
AU2011207253A1 (en
Inventor
Irina Apostolou
Paul Ponath
Joe Ponte
Michael Rosenzweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2011207253A1 publication Critical patent/AU2011207253A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request for Assignment Assignors: TOLERX, INC.
Application granted granted Critical
Publication of AU2011207253B2 publication Critical patent/AU2011207253B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2011207253A 2010-01-20 2011-01-20 Anti-ILT5 antibodies and ILT5-binding antibody fragments Ceased AU2011207253B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29679110P 2010-01-20 2010-01-20
US61/296,791 2010-01-20
PCT/US2011/021939 WO2011091177A1 (en) 2010-01-20 2011-01-20 Anti-ilt5 antibodies and ilt5-binding antibody fragments

Publications (2)

Publication Number Publication Date
AU2011207253A1 AU2011207253A1 (en) 2012-08-16
AU2011207253B2 true AU2011207253B2 (en) 2015-02-12

Family

ID=44307212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011207253A Ceased AU2011207253B2 (en) 2010-01-20 2011-01-20 Anti-ILT5 antibodies and ILT5-binding antibody fragments

Country Status (6)

Country Link
US (2) US9023997B2 (enExample)
EP (1) EP2525813B1 (enExample)
JP (1) JP2013517330A (enExample)
AU (1) AU2011207253B2 (enExample)
CA (1) CA2787783A1 (enExample)
WO (1) WO2011091177A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
EP2525822B1 (en) * 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
US20150174203A1 (en) * 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
US10097315B2 (en) * 2013-04-19 2018-10-09 Qualcomm Incorporated Group scheduling and acknowledgement for wireless transmission
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
US9985802B2 (en) * 2014-10-31 2018-05-29 Qualcomm Incorporated Channel estimation enhancements
US20180201676A1 (en) * 2015-02-11 2018-07-19 University Health Network Methods and compositions for modulating lilr proteins
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
US11787858B2 (en) 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
SG11202107663UA (en) 2019-01-18 2021-08-30 Univ Health Network Lilrb3-binding molecules and uses therefor
EP3949993A4 (en) * 2019-03-28 2023-07-05 Waseda University CELL COMPETITION INHIBITOR
EP4103613A1 (en) * 2020-02-12 2022-12-21 BioInvent International AB Lilrb3 antibody molecules and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041650A2 (en) * 2001-11-14 2003-05-22 Immunex Corporation Modulation of lir function to treat rheumatoid arthritis

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61122292A (ja) 1984-11-16 1986-06-10 Teijin Ltd 新規カルバサイクリン中間体の製法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2736076A1 (en) 1991-03-18 1992-09-19 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
US20060078564A1 (en) * 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2398251A1 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
AU2001239955A1 (en) 2000-02-28 2001-09-12 Hyseq, Inc. Novel macrophage nucleic acids and polypeptides
EP1320599A2 (en) 2000-06-28 2003-06-25 Genetics Institute, LLC Pd-l2 molecules: pd-1 ligands and uses therefor
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003051834A2 (en) 2001-12-14 2003-06-26 President And Fellows Of Harvard College Immunocellular receptors related to neurological disorders
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
EP1915394B1 (en) * 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
AU2007212683A1 (en) * 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration
CL2007000851A1 (es) * 2006-03-30 2008-03-14 Novartis Ag Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
MX2008015771A (es) 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
RU2447449C2 (ru) 2006-11-14 2012-04-10 Дженентек, Инк. Модуляторы нейрональной регенерации
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US8715941B2 (en) 2007-11-16 2014-05-06 Arca Biopharma, Inc. Antibodies to LRP6
WO2009076359A2 (en) * 2007-12-11 2009-06-18 Genentech, Inc. Modulators of neuronal regeneration
US20090285803A1 (en) 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
PE20091969A1 (es) 2008-05-13 2010-01-15 Genentech Inc ANTICUERPOS ANTI-PirB
EP2460827A1 (en) 2008-06-30 2012-06-06 The Trustees Of The University Of Pennsylvania Fusion proteins comprising Fn14 and an inhibitory protein
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
BR112012004777A2 (pt) 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
WO2012061620A1 (en) 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
AR086287A1 (es) 2011-05-05 2013-12-04 Baylor Res Inst Composicion inmunoestimulante, metodo
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041650A2 (en) * 2001-11-14 2003-05-22 Immunex Corporation Modulation of lir function to treat rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PFISTERHAMMER, K. et al Blood, Vol. 114, No. 11, page 2323-2332. 10 September 2009 *

Also Published As

Publication number Publication date
US9023997B2 (en) 2015-05-05
EP2525813B1 (en) 2017-01-04
US20150197570A1 (en) 2015-07-16
US9828425B2 (en) 2017-11-28
US20130030156A1 (en) 2013-01-31
EP2525813A4 (en) 2013-07-10
AU2011207253A1 (en) 2012-08-16
CA2787783A1 (en) 2011-07-28
JP2013517330A (ja) 2013-05-16
EP2525813A1 (en) 2012-11-28
WO2011091177A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
US9828425B2 (en) Anti-ILT5 antibodies and ILT5-binding antibody fragments
US9534051B2 (en) Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
JP7673272B2 (ja) キメラ受容体及びその使用方法
JP7384835B2 (ja) Ｃｄ３に特異的な抗体及びその使用
JP2022513778A (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
CN112513070A (zh) Il-15变体及其用途
IL296966A (en) Chimeric receptors to flt3 and methods of use thereof
CN110035769A (zh) 针对siglec-15的抗体及其使用方法
CA3125962A1 (en) Antibodies specific to human nectin-2
KR102866812B1 (ko) 신규한 항-pd-l1 항체
AU2011207257B8 (en) Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
CN119013309A (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
WO2024243093A2 (en) Multispecific antibodies targeting cd3 and cd22
HK40046552A (en) Antibodies specific for cd3 and uses thereof
HK40046552B (zh) 对cd3特异性的抗体及其用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MERCK SHARP & DOHME CORP.

Free format text: FORMER APPLICANT(S): TOLERX, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired